Fusion Pharmaceuticals Inc.(FUSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FUSN Fusion Pharmaceuticals Inc.

Market Closed 05-03 16:00:00 EDT

21.45

-0.04

-0.19%

盘后21.44

-0.01-0.05%

17:34 EDT

High21.51	Low21.43	Vol468.54K
Open21.50	D1 Closing21.49	Amplitude0.37%
Mkt Cap1.82B	Tradable Cap1.36B	Total Shares84.97M
T/O10.05M	T/O Rate0.74%	Tradable Shares63.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"FUSN","market":"US","secType":"STK","nameCN":"Fusion Pharmaceuticals Inc.","latestPrice":21.45,"timestamp":1714766400000,"preClose":21.49,"halted":0,"volume":468542,"hourTrading":{"tag":"盘后","latestPrice":21.44,"preClose":21.45,"latestTime":"17:34 EDT","volume":998,"amount":21403.8998,"timestamp":1714772093443},"delay":0,"floatShares":63369542,"shares":84965608,"eps":-1.446337,"marketStatus":"Market Closed","change":-0.04,"latestTime":"05-03 16:00:00 EDT","open":21.5,"high":21.51,"low":21.43,"amount":10048879.310292,"amplitude":0.003723,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.446337,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1714982400000},"marketStatusCode":7,"adr":0,"listingDate":1593144000000,"exchange":"NASDAQ","adjPreClose":21.49,"preHourTrading":{"tag":"盘前","latestPrice":21.49,"preClose":21.49,"latestTime":"09:03 EDT","volume":102,"amount":2194.005006,"timestamp":1714741420558},"postHourTrading":{"tag":"盘后","latestPrice":21.44,"preClose":21.45,"latestTime":"17:34 EDT","volume":998,"amount":21403.8998,"timestamp":1714772093443},"volumeRatio":0.9958769922671021},"requestUrl":"/m/hq/s/FUSN/wiki","defaultTab":"wiki","newsList":[{"id":"2432316499","title":"Radiopharma stocks higher as sector welcomes the latest M&A deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2432316499","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432316499?lang=en_us&edition=fundamental","pubTime":"2024-05-03 02:31","pubTimestamp":1714674710,"startTime":"0","endTime":"0","summary":"Shares of radiopharma companies spiked Thursday as investors welcomed the latest M&A deal to hit the sector, this time between Swiss pharma giant Novartis (NYSE:NVS) and preclinical-stage biotech Mari","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2050067813/image_2050067813.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2050067813/image_2050067813.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099035-novartis-mariana-oncology-deal-drives-radiopharma","is_publish_highlight":false,"gpt_icon":0},{"id":"2432981831","title":"Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?","url":"https://stock-news.laohu8.com/highlight/detail?id=2432981831","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432981831?lang=en_us&edition=fundamental","pubTime":"2024-05-02 22:01","pubTimestamp":1714658474,"startTime":"0","endTime":"0","summary":"Fusion Pharmaceuticals Inc.  is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.This company is expected to post quarterly loss of $0.37 per share in its upcoming report, which represents a year-over-year change of +17.8%.Revenues are expected to be $0.1 million, up 233.3% from th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Tw87WEC1wh0JNb8.IBuFMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Tw87WEC1wh0JNb8.IBuFMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fusion-pharmaceuticals-inc-fusn-expected-140114387.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430251731","title":"Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2430251731","media":"CNW Group","top":-1,"share":"https://ttm.financial/m/news/2430251731?lang=en_us&edition=fundamental","pubTime":"2024-04-26 04:34","pubTimestamp":1714077240,"startTime":"0","endTime":"0","summary":"HAMILTON, ON and BOSTON, April 25, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjucates  as precision medicines, today announced that it has filed and is in the process of mailing the management information circular and proxy statement  and related materials for the special meeting  of Fusion's shareholders  to approve the previously announced arrangement with AstraZeneca plc  under the Canada Business Corporations Act .Under the terms of the Arrangement, AstraZeneca, through a subsidiary, will acquire all of Fusion's outstanding shares for a price of US$21.00 per share in cash at closing plus a non-transferable contingent value right  representing the contingent right to receive US$3.00 per share in cash payable upon the achievement of a specified regulatory milestone, pursuant and subject to the terms and conditions of a contingent value rights agreement.Fusion also announced today that the Ontario Superio","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jioX40TUh6id.YK1PfCN3Q--~B/aD0yNDM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/0796e710ed9ac44fd246d58354c717a5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jioX40TUh6id.YK1PfCN3Q--~B/aD0yNDM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/0796e710ed9ac44fd246d58354c717a5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fusion-pharmaceuticals-mails-circular-special-203400171.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429012058","title":"Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2429012058","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2429012058?lang=en_us&edition=fundamental","pubTime":"2024-04-24 06:15","pubTimestamp":1713910516,"startTime":"0","endTime":"0","summary":"In the latest trading session, Fusion Pharmaceuticals Inc.  closed at $21.42, marking a +0.63% move from the previous day. This change lagged the S&P 500's 1.2% gain on the day. On the other hand, the Dow registered a gain of 0.69%, and the technology-centric Nasdaq increased by 1.59%.Shares of the company witnessed a gain of 0.66% over the previous month, beating the performance of the Medical sector with its loss of 5.82% and the S&P 500's loss of 4.16%.Market participants will be closely following the financial results of Fusion Pharmaceuticals Inc. in its upcoming release. On that day, Fusion Pharmaceuticals Inc. is projected to report earnings of -$0.37 per share, which would represent year-over-year growth of 17.78%. In the meantime, our current consensus estimate forecasts the revenue to be $0.1 million, indicating a 233.33% growth compared to the corresponding quarter of the prior year.Any recent changes to analyst estimates for Fusion Pharmaceuticals Inc. should also be noted ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fusion-pharmaceuticals-inc-fusn-ascends-221516006.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428530559","title":"Fusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2428530559","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428530559?lang=en_us&edition=fundamental","pubTime":"2024-04-18 06:15","pubTimestamp":1713392116,"startTime":"0","endTime":"0","summary":"Fusion Pharmaceuticals Inc.  closed the most recent trading day at $21.24, moving -0.09% from the previous trading session. This change was narrower than the S&P 500's daily loss of 0.58%. At the same time, the Dow lost 0.12%, and the tech-heavy Nasdaq lost 1.15%.The company's shares have seen an increase of 0.38% over the last month, surpassing the Medical sector's loss of 6.07% and the S&P 500's loss of 1.09%.The investment community will be paying close attention to the earnings performance of Fusion Pharmaceuticals Inc. in its upcoming release. The company is expected to report EPS of -$0.37, up 17.78% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $0.1 million, reflecting a 233.33% rise from the equivalent quarter last year.Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Fusion Pharmaceuticals Inc. These latest adjustments often mirror the shifting dynamics of short-term busin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fusion-pharmaceuticals-inc-fusn-stock-221516789.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426659227","title":"Fusion Pharmaceuticals: Market Perform Rating Amid Acquisition and Promising Prostate Cancer Treatment Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2426659227","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426659227?lang=en_us&edition=fundamental","pubTime":"2024-04-12 13:37","pubTimestamp":1712900267,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Fusion Pharmaceuticals (FUSN – Research Report) on April 9 and set a price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/fusion-pharmaceuticals-market-perform-rating-amid-acquisition-and-promising-prostate-cancer-treatment-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/fusion-pharmaceuticals-market-perform-rating-amid-acquisition-and-promising-prostate-cancer-treatment-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426021786","title":"Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2426021786","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2426021786?lang=en_us&edition=fundamental","pubTime":"2024-04-12 05:50","pubTimestamp":1712872220,"startTime":"0","endTime":"0","summary":"Fusion Pharmaceuticals Inc.  closed the most recent trading day at $21.36, making no change from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.74%. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq added 1.68%.The the stock of company has risen by 124.84% in the past month, leading the Medical sector's loss of 4.72% and the S&P 500's gain of 0.8%.The investment community will be paying close attention to the earnings performance of Fusion Pharmaceuticals Inc. in its upcoming release. The company is forecasted to report an EPS of -$0.37, showcasing a 17.78% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $0.1 million, up 233.33% from the year-ago period.Investors might also notice recent changes to analyst estimates for Fusion Pharmaceuticals Inc. Such recent modifications usually signify the changing landscape of near-term business tre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fusion-pharmaceuticals-inc-fusn-flat-215020696.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426928290","title":"Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2426928290","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2426928290?lang=en_us&edition=fundamental","pubTime":"2024-04-12 03:17","pubTimestamp":1712863077,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, Fusion Pharmaceuticals' stock price might be vulnerable to their trading decisions. A total of 10 investors have a majority stake in the company with 51% ownership. Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business. Every investor in Fusion Pharmaceuticals Inc.  should be aware of the most powerful shareholder groups. With 46% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most  from their investment into the company.Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.Let's delve deeper into each type of owner of Fusion Pharmaceuticals, beginning with the chart below.Check out our latest analysis for Fusion Pha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fusion-pharmaceuticals-inc-nasdaq-fusn-191757784.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426446740","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Fusion Pharmaceuticals (FUSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2426446740","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426446740?lang=en_us&edition=fundamental","pubTime":"2024-04-10 19:30","pubTimestamp":1712748619,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE – Research Report) and Fusion Pharmaceuticals (FUSN –...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pfizer-pfe-and-fusion-pharmaceuticals-fusn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pfizer-pfe-and-fusion-pharmaceuticals-fusn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426258861","title":"Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2426258861","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2426258861?lang=en_us&edition=fundamental","pubTime":"2024-04-10 04:05","pubTimestamp":1712693100,"startTime":"0","endTime":"0","summary":"Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer , including those who received prior lutetium-based radioconjugates. HAMILTON, ON and BOSTON, April 9, 2024 /PRNewswire/ --Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjugates  as precision medicines, today announced the presentation of interim efficacy and safety data from the Phase 2 TATCIST open-label clinical trial evaluating FPI-2265, at the American Association for Cancer Research  Annual Meeting 2024 being held April 5-10 in San Diego, California. Results demonstrate that FPI-2265 is active in heavily pretreated patients with progressive metastatic castrate-resistant prostate cancer , including patients who received prior lutetium-based RCs. Safety, tolerability and clinical activity data were generally consistent with other published studies of small molecule-based 225Ac-P","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RNYAg0JyZBchDd5mHYk8dQ--~B/aD0yNDM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0796e710ed9ac44fd246d58354c717a5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RNYAg0JyZBchDd5mHYk8dQ--~B/aD0yNDM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0796e710ed9ac44fd246d58354c717a5"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/fusion-pharmaceuticals-announces-presentation-interim-200500653.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fusion-pharmaceuticals-announces-presentation-interim-200500653.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425154603","title":"15 Most Densely Populated Cities in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2425154603","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2425154603?lang=en_us&edition=fundamental","pubTime":"2024-04-06 07:40","pubTimestamp":1712360414,"startTime":"0","endTime":"0","summary":"In this article, we will be looking at the 15 most densely populated cities in Europe. If you wish to skip our detailed analysis, you can go directly to the 5 Most Densely Populated Cities in Europe.Europe’s Population in the Broader Context of World Population. Spread over a total area of 22,134,900 sq. km, around 8,546,329 sq. miles, Europe has a population density of 34 people per sq. km, or 87 people per sq. mile. Based on estimations made by the United Nations, Europe’s population as of March 16, 2024, is 741,831,965, equivalent to around 9.32% of the total world population.Statistics by Eurostat further put the population of Europe in comparison with the world population. The continent had a population of 729 million in 2005, coming up with around 11.2% of the total world population. That ranked Europe in the lower ranks on the list of percentage of world population, with Oceania, North America, and Latin America & the Caribbean below it. In 2005, Oceania accounted for 0.5% of th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uaGKEX0co0fPstgWaFfXVA--~B/aD02NDY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/b02aebb2ae6c64b40be1c2048869453c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uaGKEX0co0fPstgWaFfXVA--~B/aD02NDY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/b02aebb2ae6c64b40be1c2048869453c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/15-most-densely-populated-cities-234014684.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424432362","title":"Wall Street Breakfast Podcast: Perma-Fix Advances In PFAS Chemical Elimination","url":"https://stock-news.laohu8.com/highlight/detail?id=2424432362","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424432362?lang=en_us&edition=fundamental","pubTime":"2024-04-04 18:50","pubTimestamp":1712227835,"startTime":"0","endTime":"0","summary":"Perma-Fix Environmental Services sees a surge in stock after successful testing for the destruction of PFAS chemicals.Ulta Beauty warns of consumer pressure from credit card debt, causing a slump in cosmetic stocks.Alphabet considers putting AI search features behind a paywall.   sitox Listen below or on the go on Apple Podcasts and Spotify","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/482730527/image_482730527.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/482730527/image_482730527.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4682114-wall-street-breakfast-podcast-perma-fix-advances-in-pfas-chemical-elimination","is_publish_highlight":false,"gpt_icon":0},{"id":"2423475851","title":"Catalyst Watch: Tesla deliveries, Disney board vote, DJT drama and Fortinet event","url":"https://stock-news.laohu8.com/highlight/detail?id=2423475851","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2423475851?lang=en_us&edition=fundamental","pubTime":"2024-03-29 03:00","pubTimestamp":1711652400,"startTime":"0","endTime":"0","summary":"Monday - April 1   Volatility watch -  Options trading volume is elevated on Trump Media & Technology (DJT). Short sellers have been under intense pressure with the stock and talk of a potential gamma","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/943292690/image_943292690.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/943292690/image_943292690.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4084622-catalyst-watch-tesla-deliveries-disney-board-vote-djt-drama-and-fortinet-event","is_publish_highlight":false,"gpt_icon":0},{"id":"2423142124","title":"What Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2423142124","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2423142124?lang=en_us&edition=fundamental","pubTime":"2024-03-29 02:49","pubTimestamp":1711651760,"startTime":"0","endTime":"0","summary":"On March 19, Fusion Pharmaceuticals (NASDAQ:FUSN) announced that it entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN)....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/what-fusion-pharmaceuticals-nasdaqfusn-acquisition-means-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/what-fusion-pharmaceuticals-nasdaqfusn-acquisition-means-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422764435","title":"Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2422764435","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2422764435?lang=en_us&edition=fundamental","pubTime":"2024-03-26 22:56","pubTimestamp":1711464960,"startTime":"0","endTime":"0","summary":"Novo Nordisk NVO announced that it would acquire Cardior Pharmaceuticals for up to 1.025 billion in an effort to strengthen its pipeline in cardiovascular disease.The purchase price includes an upfront payment and additional milestone payments if certain development and commercial milestones are achieved. The acquisition will close in the second quarter of 2024.Cardior develops therapies that target RNA to prevent, repair and reverse diseases of the heart. The agreement includes Cardior’s lead compound CDR132L, which is in mid-stage development for the treatment of heart failure.The candidate was reported to be safe and well tolerated, and the results suggested cardiac functional improvements in people with heart failure compared to placebo, per results from the phase Ib trial published in the European Heart Journal.A phase II study HF-REVERT is ongoing in 280 people with heart failure with reduced ejection fraction  who previously suffered a heart attack . The first patient was dosed ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novo-nordisk-nvo-buy-cardior-145600864.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422527200","title":"31 European Countries That Offer Citizenship by Descent","url":"https://stock-news.laohu8.com/highlight/detail?id=2422527200","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2422527200?lang=en_us&edition=fundamental","pubTime":"2024-03-26 02:52","pubTimestamp":1711392741,"startTime":"0","endTime":"0","summary":"In this article, we will take a look at 31 European Countries That Offer Citizenship by Descent. You can skip our detailed analysis and go directly to the 11 European Countries That Offer Citizenship by Descent.A report by GLOBALCIT in 2020 observed that a majority of EU member state citizens acquire their citizenship through birth, primarily through descent . However, the procedures for citizenship vary for individuals born to citizens within the country compared to those born to a citizen abroad. Between 2013 and 2020, certain changes regarding ius sanguinis were implemented in some EU member states, including the possibility of citizenship based on more remote ancestry. For example, in 2015, Portugal allowed the grant of citizenship through registration without the residence requirement to a person born abroad who is a grandchild of a citizen. However, this was conditional on the grandparent not having lost their Portuguese citizenship and being of Portugues","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DyaXhjKTn1uhIuBuRIM45A--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/170ef676721a3e04063cf93ac2345106","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DyaXhjKTn1uhIuBuRIM45A--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/170ef676721a3e04063cf93ac2345106"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/31-european-countries-offer-citizenship-185221500.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422525921","title":"2 More Potential Biotech Buyout Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2422525921","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422525921?lang=en_us&edition=fundamental","pubTime":"2024-03-26 01:07","pubTimestamp":1711386452,"startTime":"0","endTime":"0","summary":"M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4680296-2-more-potential-biotech-buyout-targets","is_publish_highlight":false,"gpt_icon":0},{"id":"2422982544","title":"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq -","url":"https://stock-news.laohu8.com/highlight/detail?id=2422982544","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2422982544?lang=en_us&edition=fundamental","pubTime":"2024-03-25 23:10","pubTimestamp":1711379400,"startTime":"0","endTime":"0","summary":"BALA CYNWYD, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22972857","is_publish_highlight":false,"gpt_icon":0},{"id":"2421825838","title":"Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2421825838","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2421825838?lang=en_us&edition=fundamental","pubTime":"2024-03-22 23:59","pubTimestamp":1711123140,"startTime":"0","endTime":"0","summary":"This week AstraZeneca AZN announced a definitive agreement to acquire Fusion Therapeutics FUSN to accelerate the development of next-generation radioconjugates to treat cancer. Pfizer PFE plans to sell some shares of consumer healthcare firm Haleon to bring down its stake from 32% to 24%. An FDA advisory committee voted unanimously for expanding the use of J&J’s JNJ CAR-T therapy, Carvykti, for earlier lines of multiple myeloma. Merck’s MRK phase III study evaluating a Keytruda-based combination in a first-line lung cancer indication failed to meet its primary goals.FDA Advisory Panel Votes for Expanded Use of J&J’s Carvykti: The FDA’s Oncologic Drugs Advisory Committeevoted unanimously to recommend the expanded use of J&J’s multiple myeloma drug Carvykti for earlier lines of treatment based on data from the phase III CARTITUDE-4 study. J&J is looking for the expansion of Carvykti’s label to include treatment of adult patients with relapsed or refractory multiple myeloma who have recei","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/._mAv70PW7IAFz5cM1Tjpg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/._mAv70PW7IAFz5cM1Tjpg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-azn-buy-155900371.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fusionpharma.com","stockEarnings":[{"period":"1week","weight":0.0014},{"period":"1month","weight":0.0052},{"period":"3month","weight":1.0236},{"period":"6month","weight":3.6937},{"period":"1year","weight":4.2574},{"period":"ytd","weight":1.232}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.232831},{"month":2,"riseRate":1,"avgChangeRate":0.131408},{"month":3,"riseRate":0.5,"avgChangeRate":0.146308},{"month":4,"riseRate":0.5,"avgChangeRate":-0.124248},{"month":5,"riseRate":0.5,"avgChangeRate":-0.003948},{"month":6,"riseRate":0,"avgChangeRate":-0.141704},{"month":7,"riseRate":0.25,"avgChangeRate":-0.143007},{"month":8,"riseRate":0.25,"avgChangeRate":-0.014692},{"month":9,"riseRate":0.25,"avgChangeRate":0.005874},{"month":10,"riseRate":0.5,"avgChangeRate":0.125937},{"month":11,"riseRate":0.5,"avgChangeRate":0.011293},{"month":12,"riseRate":0.5,"avgChangeRate":0.177754}],"exchange":"NASDAQ","name":"Fusion Pharmaceuticals Inc.","nameEN":"Fusion Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fusion Pharmaceuticals Inc.(FUSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fusion Pharmaceuticals Inc.(FUSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fusion Pharmaceuticals Inc.,FUSN,Fusion Pharmaceuticals Inc.股票,Fusion Pharmaceuticals Inc.股票老虎,Fusion Pharmaceuticals Inc.股票老虎国际,Fusion Pharmaceuticals Inc.行情,Fusion Pharmaceuticals Inc.股票行情,Fusion Pharmaceuticals Inc.股价,Fusion Pharmaceuticals Inc.股市,Fusion Pharmaceuticals Inc.股票价格,Fusion Pharmaceuticals Inc.股票交易,Fusion Pharmaceuticals Inc.股票购买,Fusion Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fusion Pharmaceuticals Inc.(FUSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fusion Pharmaceuticals Inc.(FUSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction